Loading...

Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update

Malignancy after solid organ transplantation remains a major cause of posttransplant mortality. The mammalian target of rapamycin (mTOR) inhibitor class of immunosuppressants exerts various antioncogenic effects, and the mTOR inhibitor everolimus is licensed for the treatment of several solid cancer...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Transplant
Main Authors: Holdaas, Hallvard, De Simone, Paolo, Zuckermann, Andreas
Format: Artigo
Sprog:Inglês
Udgivet: Hindawi Publishing Corporation 2016
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5078653/
https://ncbi.nlm.nih.gov/pubmed/27807479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2016/4369574
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!